Eaton Vance Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Eaton Vance Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$5.41M	Buy	87,352 +656	+0.8%	+$45.8K	0.01%	755
2022 Q2	$6.92M	Sell	86,696 -5,227	-6%	-$495K	0.01%	713
2022 Q1	$9.67M	Buy	91,923 +54,813	+148%	+$5.34M	0.01%	700
2021 Q4	$4M	Sell	37,110 -590	-2%	-$64.4K	﹤0.01%	836
2021 Q3	$4.05M	Buy	37,700 +700	+2%	+$72.7K	0.01%	770
2021 Q2	$3.46M	Buy	37,000 +8,343	+29%	+$768K	﹤0.01%	877
2021 Q1	$2.64M	Buy	28,657 +1,494	+6%	+$126K	﹤0.01%	910
2020 Q4	$1.99M	Buy	27,163 +15	+0.1%	+$1.11K	﹤0.01%	927
2020 Q3	$2.11M	Hold	27,148	–	–	﹤0.01%	825
2020 Q2	$1.51M	Sell	27,148 -270	-1%	-$11.6K	﹤0.01%	873
2020 Q1	$812K	Buy	27,418 +199	+0.7%	+$6.73K	﹤0.01%	964
2019 Q4	$985K	Buy	27,219 +108	+0.4%	+$3.31K	﹤0.01%	995
2019 Q3	$738K	Buy	27,111 +111	+0.4%	+$2.87K	﹤0.01%	1039
2019 Q2	$650K	Hold	27,000	–	–	﹤0.01%	1056
2019 Q1	$714K	Hold	27,000	–	–	﹤0.01%	996
2018 Q4	$528K	Hold	27,000	–	–	﹤0.01%	986
2018 Q3	$529K	Hold	27,000	–	–	﹤0.01%	1015
2018 Q2	$447K	Sell	27,000 -27,000	-50%	-$412K	﹤0.01%	1026
2018 Q1	$766K	Buy	54,000 +27,000	+100%	+$399K	﹤0.01%	1020
2017 Q4	$394K	Hold	27,000	–	–	﹤0.01%	1004
2017 Q3	$342K	Hold	27,000	–	–	﹤0.01%	1009
2017 Q2	$320K	Hold	27,000	–	–	﹤0.01%	1003
2017 Q1	$399K	Sell	27,000 -171	-0.6%	-$2.77K	﹤0.01%	935
2016 Q4	$440K	Buy	27,171 +171	+0.6%	+$3.1K	﹤0.01%	878
2016 Q3	$490K	Hold	27,000	–	–	﹤0.01%	846
2016 Q2	$445K	Hold	27,000	–	–	﹤0.01%	839
2016 Q1	$447K	Hold	27,000	–	–	﹤0.01%	804
2015 Q4	$585K	Buy	+27,000	New	+$526K	﹤0.01%	777

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Eaton Vance Management's HZNP Position: Q3 2022 in Review

Eaton Vance Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 0.76% in Q3 2022, buying an estimated $45.8K and bringing the position to 87,352 shares worth $5.41M. The position accounts for 0.01% of the portfolio, ranked #755.

Eaton Vance Management first reported a position in HZNP in Q4 2015 and has held it in 28 quarters since. The position peaked at $9.67M in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Eaton Vance Management held 87,352 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.41M as of Q3 2022.
Eaton Vance Management bought 656 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $45.8K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #755 holding.
Eaton Vance Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and has held it in 28 quarters since.
Eaton Vance Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.67M in Q1 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.